In 2006, the National Cancer Institute announced that raloxifene was as effective as tamoxifen in reducing the incidence of breast cancer in postmenopausal women at increased risk. A major adverse effect of tamoxifen is uterine cancer; raloxifene caused fewer cases of uterine cancer. Tamoxifen increased the risk of cataracts, but raloxifene did no...
Found on
http://en.wikipedia.org/wiki/Raloxifene
The active ingredient in a drug used to reduce the risk of invasive breast cancer in postmenopausal women who are at high risk of the disease or who have osteoporosis. It is also used to prevent and treat osteoporosis in postmenopausal women. It is also being studied in the prevention of breast cancer in certain premenopausal women and in the preve...
Found on
http://www.cancer.gov/dictionary?expand=R
(ral-ok´sĭ-fēn) a selective estrogen receptor modulator that has estrogenlike effects on bone, increasing bone mineral density, and lipid metabolism, lowering total and LDL cholesterol; it has no effect on breast or uterine tissue. Administered orally as the hydrochloride salt for the prevention of postmenopau...
Found on
http://www.encyclo.co.uk/local/21001
Type: Term Pronunciation: ral-ox′ĭ-fēn Definitions: 1. A selective estrogen receptor modulator (SERM) that has estrogen-agonistic effects on bone and lipid metabolism but estrogen-antagonistic effects on breast and uterus; used in the prophylaxis of osteoporosis after menopause.
Found on
http://www.medilexicon.com/medicaldictionary.php?t=75119
No exact match found.
